宜明昂科(01541.HK)IMM2510/AXN-2510联合化疗2期试验结果预计下半年公布

阿斯达克财经
May 22

宜明昂科-B(01541.HK) 公布,连同Instil Bio, Inc.宣布IMM2510/AXN-2510的临床最新情况及未来计划。预计将于今年第三季度在内地完成成IMM2510/AXN-2510联合化疗治疗一线NSCLC患者的2期试验的约60名患者入组,而2期试验的初步安全性及有效性结果预计将于今年下半年公布。3期试验预计明年年中在内地启动,目前尚待与监管部门商讨。

IMM2510/AXN-2510是一种PD-L1和VEGF的双特异性抗体,目前正开发用于治疗多种实体肿瘤癌症。(de/d)(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10